Little Benefit From Pfizer Inc. & Bristol-Myers Squibb Company Bloodthinner
Published: Mar 16, 2012
Pfizer Inc. (PFE) and Bristol-Myers Squibb Co. (BMY)’s Eliquis offered little to no added benefit for patients who had undergone elective hip or knee replacement surgery when compared to Sanofi’s Lovenox, a German health agency said today. The Institute for Quality and Efficiency in Health Care, otherwise known as IQWiG, said the newer medicine offered no added benefit for prevention of venous thromboembolic events in knee surgery patients. Eliquis, known chemically as apixaban, offered a low additional benefit for hip surgery patients, the agency said in a statement posted on its website today.